Shaheen NJ, Hansen RA, Morgan DR, et al.: The burden of gastrointestinal and liver diseases, 2006. Am J Gastroenterol 2006, 101:2128–2138.
Laine L, Ahnen D, McClain C, et al.: Review article: potential gastrointestinal effects of long-term acid suppression with proton pump inhibitors. Aliment Pharmacol Ther 2000, 14:651–668.
Hill AB: The environment and disease: association or causation?
Proc R Soc Med 1965, 58:295–300.
Thorens J, Froehlich F, Schwizer W, et al.: Bacterial over-growth during treatment with omeprazole compared with cimetidine: a prospective randomised double blind study. Gut 1996, 39:54–59.
Dial S, Alrasadi K, Manoukian C, et al.: Risk of Clostridium difficile diarrhea among hospital impatients prescribed proton pump inhibitors: cohort and case-control studies. CMAJ 2004, 171:33–38.
Leonard J, Marshall JK, Moayyedi P: Systematic review of the risk of enteric infection in patients taking acid suppression. Am J Gastroenterol 2007, 102:2047–2056; quiz 2057.
Shah S, Lewis A, Leopold D, et al.: Gastric acid suppression does not promote clostridial diarrhoea in the elderly. QJM 2000, 93:175–181.
Loo VG, Poirier L, Miller MA, et al.: A predominantly clonal multi-institutional outbreak of Clostridium difficile-associated diarrhea with high morbidity and mortality. N Engl J Med 2005, 353:2442–2449.
Laheij RJ, Sturkenboom MC, Hassing RJ, et al.: Risk of community-acquired pneumonia and use of gastric acid-suppressive drugs. JAMA 2004, 292:1955–1960.
Gulmez SE, Holm A, Frederiksen H, et al.: Use of proton pump inhibitors and the risk of community-acquired pneumonia: a population-based case-control study. Arch Intern Med 2007, 167:950–955.
Laheij RJ, Van Ijzendoorn MC, Janssen MJ, Jansen JB: Gastric acid-suppressive therapy and community-acquired respiratory infections. Aliment Pharmacol Ther 2003, 18:847–851.
Canani RB, Cirillo P, Roggero P, et al.: Therapy with gastric acidity inhibitors increases the risk of acute gastroenteritis and community-acquired pneumonia in children. Pediatrics 2006, 117:e817–e820.
Sarkar MA, Yang YX: Are proton pump inhibitors (PPIs) associated with an increased risk of community-acquired pneumonia (CAP)? A nested case control study investigating recent PPI exposure and CAP [abstract]. Am J Gastroenterol 2007, 102:S446.
Chonan O, Takahashi R, Yasui H, Watanuki M: Effect of L-lactic acid on calcium absorption in rats fed omeprazole. J Nutr Sci Vitaminol (Tokyo) 1998, 44:473–481.
Bo-Linn GW, Davis GR, Buddrus DJ, et al.: An evaluation of the importance of gastric acid secretion in the absorption of dietary calcium. J Clin Invest 1984, 73:640–647.
Recker RR: Calcium absorption and achlorhydria. N Engl J Med 1985, 313:70–73.
O’Connell MB, Madden DM, Murray AM, et al.: Effects of proton pump inhibitors on calcium carbonate absorption in women: a randomized crossover trial. Am J Med 2005, 118:778–781.
Mattsson JP, Vaananen K, Wallmark B, Lorentzon P: Omeprazole and bafilomycin, two proton pump inhibitors: differentiation of their effects on gastric, kidney and bone H(+)-translocating ATPases. Biochim Biophys Acta 1991, 1065:261–268.
Kocsis I, Arato A, Bodanszky H, et al.: Short-term omeprazole treatment does not influence biochemical parameters of bone turnover in children. Calcif Tissue Int 2002, 71:129–132.
Mizunashi K, Furukawa Y, Katano K, Abe K: Effect of omeprazole, an inhibitor of H+,K(+)-ATPase, on bone resorption in humans. Calcif Tissue Int 1993, 53:21–25.
Hollowell J: The General Practice Research Database: quality of morbidity data. Popul Trends 1997, Spring:36–40.
Yang YX, Lewis JD, Epstein S, Metz DC: Long-term proton pump inhibitor therapy and risk of hip fracture. JAMA 2006, 296:2947–2953.
Geller JL, Adams JS: Proton pump inhibitor therapy and hip fracture risk. JAMA 2007, 297:1429; author reply 1429–1430.
Vestergaard P, Rejnmark L, Mosekilde L: Proton pump inhibitors, histamine H2 receptor antagonists, and other antacid medications and the risk of fracture. Calcif Tissue Int 2006, 79:76–83.
Howden CW: Vitamin B12 levels during prolonged treatment with proton pump inhibitors. J Clin Gastroenterol 2000, 30:29–33.
Schenk BE, Festen HP, Kuipers EJ, et al.: Effect of short-and long-term treatment with omeprazole on the absorption and serum levels of cobalamin. Aliment Pharmacol Ther 1996, 10:541–545.
Koop H, Bachem MG: Serum iron, ferritin, and vitamin B12 during prolonged omeprazole therapy. J Clin Gastroenterol 1992, 14:288–292.
Valuck RJ, Ruscin JM: A case-control study on adverse effects: H2 blocker or proton pump inhibitor use and risk of vitamin B12 deficiency in older adults. J Clin Epidemiol 2004, 57:422–428.
Force RW, Meeker AD, Cady PS, et al.: Ambulatory care increased vitamin B12 requirement associated with chronic acid suppression therapy. Ann Pharmacother 2003, 37:490–493.
Hutchinson C, Geissler CA, Powell JJ, Bomford A: Proton pump inhibitors suppress absorption of dietary non-haem iron in hereditary haemochromatosis. Gut 2007, 56:1291–1295.
Stewart CA, Termanini B, Sutliff VE, et al.: Iron absorption in patients with Zollinger-Ellison syndrome treated with long-term gastric acid antisecretory therapy. Aliment Pharmacol Ther 1998, 12:83–98.
Larsson H, Carlsson E, Mattsson H, et al.: Plasma gastrin and gastric enterochromaffinlike cell activation and proliferation. Studies with omeprazole and ranitidine in intact and antrectomized rats. Gastroenterology 1986, 90:391–399.
Rindi G, Luinetti O, Cornaggia M, et al.: Three subtypes of gastric argyrophil carcinoid and the gastric neuroendocrine carcinoma: a clinicopathologic study. Gastroenterology 1993, 104:994–1006.
Peghini PL, Annibale B, Azzoni C, et al.: Effect of chronic hypergastrinemia on human enterochromaffin-like cells: insights from patients with sporadic gastrinomas. Gastroenterology 2002, 123:68–85.
Modlin IM, Lye KD, Kidd M: A 50-year analysis of 562 gastric carcinoids: small tumor or larger problem?
Am J Gastroenterol 2004, 99:23–32.
Lamberts R, Brunner G, Solcia E: Effects of very long (up to 10 years) proton pump blockade on human gastric mucosa. Digestion 2001, 64:205–213.
Solcia E, Fiocca R, Havu N, et al.: Gastric endocrine cells and gastritis in patients receiving long-term omeprazole treatment. Digestion 1992, 51(Suppl 1):82–92.
Klinkenberg-Knol EC, Nelis F, Dent J, et al.: Long-term omeprazole treatment in resistant gastroesophageal reflux disease: efficacy, safety, and influence on gastric mucosa. Gastroenterology 2000, 118:661–669.
Eslick GD, Lim LL, Byles JE, et al.: Association of Helicobacter pylori infection with gastric carcinoma: a meta-analysis. Am J Gastroenterol 1999, 94:2373–2379.
Kuipers EJ, Nelis GF, Klinkenberg-Knol EC, et al.: Cure of Helicobacter pylori infection in patients with reflux oesophagitis treated with long term omeprazole reverses gastritis without exacerbation of reflux disease: results of a randomised controlled trial. Gut 2004, 53:12–20.
Kuipers EJ: Proton pump inhibitors and gastric neoplasia. Gut 2006, 55:1217–1221.
Watson SA, Smith AM: Hypergastrinemia promotes adenoma progression in the APC(Min-/+) mouse model of familial adenomatous polyposis. Cancer Res 2001, 61:625–631.
Thorburn CM, Friedman GD, Dickinson CJ, et al.: Gastrin and colorectal cancer: a prospective study. Gastroenterology 1998, 115:275–280.
Yang YX, Hennessy S, Propert K, et al.: Chronic proton pump inhibitor therapy and the risk of colorectal cancer. Gastroenterology 2007, 133:748–754.
Robertson DJ, Larsson H, Friis S, et al.: Proton pump inhibitor use and risk of colorectal cancer: a population-based, case-control study. Gastroenterology 2007, 133:755–760.
Cahan MA, Balduf L, Colton K, et al.: Proton pump inhibitors reduce gallbladder function. Surg Endosc 2006, 20:1364–1367.
Chowdhury JR, Berkowitz JM, Praissman M, Fara JW: Effect of sulfated and non-sulfated gastrin and octapeptide-cholecystokinin on cat gall bladder in vitro. Experientia 1976, 32:1173–1175.
Geevasinga N, Coleman PL, Webster AC, Roger SD: Proton pump inhibitors and acute interstitial nephritis. Clin Gastroenterol Hepatol 2006, 4:597–604.
Sierra F, Suarez M, Rey M, Vela MF: Systematic review: proton pump inhibitor-associated acute interstitial nephritis. Aliment Pharmacol Ther 2007, 26:545–553.
Cote GA, Ferreira MR, Rozenberg-Ben-Dror K, Howden CW: Programme of stepping down from twice daily proton pump inhibitor therapy for symptomatic gastro-oesophageal reflux disease associated with a formulary change at a VA medical center. Aliment Pharmacol Ther 2007, 25:709–714.